Merck & Co.: mRNA Success With Moderna Could Give Keytruda New Momentum
Reading Time: 3 minutes
Moderna and Merck impress with phase 3 study data on the combination of the mRNA cancer vaccine Intismeran and the immunotherapy Keytruda. The second quarter was convincing with a revenue increase of 5%, primarily driven by the cancer drug Keytruda and new product launches. Due to the acquisition of Terns Pharmaceuticals for $5.7 billion, completed in May 2026, the earnings forecast for fiscal year 2026 had to be lowered. While Moderna (MRNA) was listed pre-market on August 19 with an increase of over 100%, Merck & Co....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
